Rotavirus vaccine
Emerging Scandal in Vaccine Mandates
In
its initial trial, the rotavirus vaccine appeared to cause intussusception at 30
times the average rate, but the government pretended that those injuries were
insignificant. Instead of testing further, the CDC and the vaccine manufacturer
subjected babies to more than a million doses of this unnecessary, expensive,
and inadequately tested vaccine.
While
the risk of intussusception may have been mentioned on the package insert, it
was not on the vaccine information statement given to parents. The arbitrariness
of government vaccine mandates is shown by the fact that, for the previous year,
CDC was demanding that the vaccine be given to all infants, and now suddenly a
CDC spokesman is saying, "No one should now be giving rotavirus vaccine to
anyone."
Burton
Critical of Vaccine Approval Process
The
report focuses on the advisory committees' review of the controversial rotavirus
vaccine in 1997 and 1998. Despite concerns about potentially serious side
effects of the drug, it won unanimous votes of support in both committees.
Within one year, the vaccine, made by Wyeth Lederle had to be pulled from the
market because it was causing severe bowel obstructions in infants that required
surgery to correct. One baby died.
The
Committee found that three out of the five full-time FDA advisory committee
members who voted for the vaccine had financial ties to Wyeth Lederle or tow
companies developing rival rotavirus vaccines...Merck and SmithKline Beecham.
Four out of eight CDC advisory committee members who supported the vaccine had
conflicts with the same companies. The staff report concludes that the
committees demonstrated a "lack of vigilance" in their review of the
rotavirus vaccine known as "Rotashield", with the CDC's committee
rushing to approve guidelines for the vaccine even before the FDA had licensed
it.
One
physician who voted to recommend the rotavirus vaccine on the FDA's advisory
committee received $255,000.00 per year in research funds from the maker of the
vaccine, Wyeth Lederle. She received a waiver from the FDA to vote on the
issue because her research for Wyeth focused on other vaccines.
One
member of the CDC's advisory committee who was not allowed to vote on the
rotavirus vaccine because of a conflict was allowed to participate in
closed-door working group meetings that drafted the committee's recommendations
for the vaccine. He was also allowed to make an impassioned plea for
approval of the vaccine at the full committee hearing.
Another
member of the CDC's advisory committee held a lucrative patent on a rival
rotavirus vaccine under development by Merck. Despite this conflict, the
doctor voted three times on recommendations regarding Wyeth's vaccine. It
was not until the committee voted to rescind its recommendation of the
rotashield that he recused himself because of a "perception of
conflict".